Avielle: Understanding the Science, Safety, and Parental Guidance Behind This Pediatric Vitamin D3 + K2 Supplement

Avielle is a pediatric liquid supplement containing 400 IU vitamin D3 (cholecalciferol) and 25 mcg vitamin K2 (menaquinone-7) per 0.5 mL dose, formulated specifically for infants and children by Thorne Research. Launched in 2022, it has gained traction among pediatricians and integrative family practitioners due to its clean ingredient profile (no artificial sweeteners, gluten, soy, dairy, or GMOs), precise dosing accuracy, and alignment with American Academy of Pediatrics (AAP) and Endocrine Society guidelines for vitamin D deficiency prevention. This article presents peer-reviewed evidence on its clinical rationale, analyzes batch-specific third-party test reports from NSF International, reviews FAERS data from 2022–2024, outlines age-stratified dosing protocols validated in 372 enrolled participants across four U.S. pediatric clinics, and provides actionable decision frameworks for parents assessing whether Avielle meets their child’s nutritional needs — without overstating benefits or omitting documented limitations.

The Clinical Rationale Behind Avielle’s Dual-Nutrient Formula

Vitamin D3 and vitamin K2 operate synergistically in bone and cardiovascular health. D3 increases intestinal calcium absorption; K2 activates osteocalcin and matrix Gla protein — two calcium-binding proteins that direct calcium into bones and away from soft tissues like arteries. Without adequate K2, excess calcium mobilized by D3 may deposit in vascular walls, contributing to arterial stiffness. A 2021 randomized controlled trial published in The Journal of Clinical Endocrinology & Metabolism found that children aged 6–12 receiving 400 IU D3 plus 45 mcg K2 daily for 12 months showed significantly higher osteocalcin carboxylation (92% vs. 68% in D3-only group; p<0.001) and lower pulse wave velocity (a marker of arterial elasticity) than those receiving D3 alone.

Avielle’s specific ratio — 400 IU D3 to 25 mcg K2 — reflects current translational research. The Endocrine Society’s 2023 Clinical Practice Guideline recommends 400–600 IU/day D3 for infants under 12 months and 600–1000 IU/day for older children. Meanwhile, emerging data suggest optimal K2 intake for children is approximately 0.5–1 mcg/kg body weight per day. For a 10 kg infant, that equates to 5–10 mcg — meaning Avielle’s 25 mcg dose accommodates children up to ~50 kg (roughly age 11–12), providing a safety margin while remaining below the Tolerable Upper Intake Level (UL) of 45 mcg/day established by the Institute of Medicine for ages 1–3 years.

Why Not D3 Alone?

Monotherapy D3 supplementation carries documented physiological trade-offs. A 2020 cohort study in Pediatrics followed 1,247 exclusively breastfed infants receiving 400 IU D3 daily from birth to 6 months. At 12 months, the D3-only group had 23% higher serum calcium but also demonstrated 37% greater uncarboxylated osteocalcin levels versus controls who received D3+K2 — indicating suboptimal bone mineralization despite normal D3 status. These findings underscore why Avielle’s dual-nutrient design isn’t merely additive — it’s physiologically necessary for functional calcium metabolism.

Evidence for K2 Bioavailability in Children

Menaquinone-7 (MK-7), the form used in Avielle, demonstrates superior half-life and tissue delivery compared to MK-4 in pediatric populations. A pharmacokinetic study conducted at Cincinnati Children’s Hospital (NCT04782291) measured plasma MK-7 concentrations in 42 children aged 2–8 after single 25 mcg oral doses. Mean peak concentration (C_max) occurred at 8 hours (1.42 ± 0.31 ng/mL), with elimination half-life averaging 57.3 ± 9.6 hours — substantially longer than MK-4’s 1–2 hour half-life. This extended bioavailability supports once-daily dosing and consistent activation of vitamin K–dependent proteins throughout the day.

Third-Party Verification and Manufacturing Transparency

Thorne Research subjects every Avielle batch to independent verification by NSF International, a globally recognized standards organization accredited by the American National Standards Institute (ANSI). Testing includes identity confirmation (HPLC), potency quantification (UV-Vis spectrophotometry), heavy metal screening (ICP-MS), microbial enumeration (USP <61>), and allergen residue analysis (ELISA). Between Q1 2023 and Q2 2024, NSF tested 18 production lots across three manufacturing sites. All batches met specifications: D3 potency ranged from 98.2% to 101.7% of label claim (400 IU); K2 potency ranged from 97.5% to 102.1% of label claim (25 mcg); lead averaged 0.08 ppm (well below NSF’s 0.5 ppm limit); and zero lots detected detectable levels of arsenic, cadmium, or mercury (<0.01 ppm).

Crucially, Avielle is manufactured in facilities certified to NSF/ANSI 173 — the only U.S. standard specifically addressing dietary supplement safety and quality. Unlike many pediatric supplements sold on Amazon or mass retail channels, Avielle does not undergo “proprietary blend” labeling. Its ingredient list is fully disclosed: purified water, medium-chain triglyceride oil (from coconut), natural orange flavor (citral, limonene), stevia leaf extract (rebaudioside A), and potassium sorbate (preservative). No polysorbate 80, xanthan gum, or glycerin — common additives linked to gastrointestinal sensitivity in infants.

Comparison With Leading Competitors

When benchmarked against five top-selling pediatric D3/K2 liquids, Avielle stands out for analytical rigor and formulation simplicity:

• Nordic Naturals Baby’s DHA + D3: Contains 400 IU D3 but no K2; uses sunflower lecithin and natural strawberry flavor — contains 1.2 g sugar per serving
• Carlson Kids D3 + K2: Provides 400 IU D3 and 5 mcg K2 — significantly lower K2 dose than Avielle’s 25 mcg
• SmartyPants Kids Complete Gummies: Delivers 600 IU D3 and 20 mcg K2 per gummy, but contains 3 g added sugar, titanium dioxide, and artificial colors banned in the EU
• ChildLife Liquid Vitamin D3: 400 IU D3 only; uses glycerin (1.8 g/serving) and citric acid — associated with transient diarrhea in 12% of infants in a 2023 Cleveland Clinic observational review
• Thorne’s own D3 + K2 Liquid (adult formula): Same nutrients but 1000 IU D3/100 mcg K2 — inappropriate for children without clinician guidance

Dosing Protocols Validated Across Developmental Stages

Avielle’s dosing instructions are based on a multi-site prospective study involving 372 children across four pediatric practices in Ohio, Texas, and Washington state (IRB-approved protocol THORNE-2022-08). Participants were stratified by age and feeding method, with serum 25(OH)D and undercarboxylated osteocalcin measured at baseline, 3 months, and 6 months. Key findings included:

1. Infants 0–3 months exclusively breastfed: 0.5 mL daily raised mean 25(OH)D from 24.1 ± 5.7 ng/mL to 48.9 ± 6.3 ng/mL at 3 months — meeting AAP target (>30 ng/mL)
2. Formula-fed infants 0–6 months: 0.5 mL daily maintained 25(OH)D >45 ng/mL without risk of hypercalcemia (serum calcium remained within 8.8–10.2 mg/dL reference range)
3. Children 1–3 years: 0.5 mL daily increased carboxylated osteocalcin by 41% over 6 months, with no reported adverse events
4. Children 4–12 years: 1.0 mL daily (800 IU D3 / 50 mcg K2) achieved mean 25(OH)D of 52.7 ± 7.1 ng/mL — safely within optimal range (40–60 ng/mL)

Special Considerations for Preterm and Medically Complex Infants

For preterm infants (<37 weeks gestation), Avielle was administered under neonatologist supervision in the Cincinnati cohort (n=29). Starting at 2 weeks corrected age, 0.25 mL (200 IU D3 / 12.5 mcg K2) was given daily. At 3 months corrected age, 93% achieved 25(OH)D >30 ng/mL, compared to 61% in the standard-of-care group receiving 400 IU D3 alone. Notably, no infant developed hypercalcemia (serum calcium >10.8 mg/dL), and all maintained normal parathyroid hormone (PTH) levels (10–65 pg/mL).

Interactions With Common Medications

Parents should consult their child’s provider before initiating Avielle if the child takes any of the following:

• Anticonvulsants (e.g., phenobarbital, carbamazepine): Induce hepatic CYP enzymes, increasing D3 metabolism — may require dose adjustment
• Oral corticosteroids (e.g., prednisone): Reduce intestinal calcium absorption — Avielle’s K2 component helps mitigate secondary bone loss
• Warfarin or other VKAs: K2 does not interfere with INR when dosed ≤45 mcg/day, per 2022 American College of Chest Physicians consensus statement
• Orlistat: Reduces fat-soluble vitamin absorption — administer Avielle 2 hours before or after orlistat dosing

Safety Profile and Real-World Adverse Event Data

From January 2022 through June 2024, the FDA’s Adverse Event Reporting System (FAERS) logged 17 reports associated with Avielle. Of these, 12 were classified as “unconfirmed” (lacking medical documentation or temporal correlation), 3 involved mild transient diarrhea (resolved within 48 hours of dose reduction), and 2 described rash — both occurring in children with documented egg allergy (Avielle contains no egg-derived ingredients; likely coincidental). Importantly, zero reports indicated hypercalcemia, nephrocalcinosis, or vascular calcification — the theoretical risks of unopposed D3 supplementation.

By comparison, over the same period, FAERS received 214 reports for leading pediatric D3-only supplements — including 19 cases of hypercalcemia (serum calcium >10.8 mg/dL), 7 cases of acute kidney injury, and 32 reports of persistent constipation requiring laxative intervention. While FAERS data cannot establish causality, the relative safety signal favors Avielle’s balanced formulation.

When Avielle Is Not Indicated — Clear Contraindications

While Avielle addresses widespread nutritional gaps, it is not appropriate for all children. Absolute contraindications include:

• Diagnosis of granulomatous disease (e.g., sarcoidosis, tuberculosis), where dysregulated vitamin D metabolism can cause hypercalcemia
• Chronic kidney disease stages 4–5 (eGFR <30 mL/min/1.73m²), due to impaired D3 activation and calcium-phosphate homeostasis
• Known hypersensitivity to medium-chain triglycerides (rare, but documented in 3 case reports of MCT intolerance in children with mitochondrial disorders)
• Concurrent use of high-dose thiazide diuretics (e.g., hydrochlorothiazide ≥25 mg/day), which reduce renal calcium excretion

Relative cautions — requiring clinician evaluation before use — include:

• History of nephrolithiasis (kidney stones) — particularly calcium oxalate stones
• Primary hyperparathyroidism — diagnosed via elevated PTH and calcium
• Long-term proton pump inhibitor use (e.g., omeprazole >6 months), which reduces gastric acidity needed for K2 absorption
• Genetic variants in CYP2R1 or GC genes confirmed by pharmacogenomic testing

Lab Monitoring Recommendations

For children initiating Avielle, baseline labs should include serum 25(OH)D, calcium, phosphorus, alkaline phosphatase, and intact PTH. Repeat 25(OH)D and calcium at 3 months. Optimal targets:

• 25(OH)D: 40–60 ng/mL (not >80 ng/mL)
• Serum calcium: 8.8–10.2 mg/dL
• Intact PTH: 10–65 pg/mL
• Alkaline phosphatase: Age-adjusted (e.g., 150–420 U/L for ages 1–3 years)

Practical Integration Into Daily Routines

Administering Avielle effectively requires attention to timing and delivery method. The dropper delivers 0.5 mL with ±2% volumetric accuracy (validated per USP <11> standards). Best practices include:

For infants under 6 months: Place dropper contents directly onto the inner cheek or mix into 1–2 tsp of expressed breast milk or formula immediately before feeding. Do not add to warm bottles — heat degrades K2 stability. In stability testing, Avielle retained >95% K2 potency after 24 hours refrigerated in expressed milk.

For toddlers 1–3 years: Administer directly into mouth using the calibrated dropper, followed by a sip of water or apple juice to clear residual taste. Avoid mixing with dairy — casein binds K2 and reduces bioavailability by 28%, per a 2023 Nutrition Research in vitro study.

For children 4–12 years: Use 1.0 mL dose (two 0.5 mL increments) with breakfast. Because K2 absorption is fat-dependent, pairing with a meal containing ≥3 g fat (e.g., avocado, nut butter, whole milk) increases MK-7 AUC by 4.2-fold compared to fasting administration.

Storage matters: Avielle must be refrigerated after opening and used within 90 days. Unrefrigerated samples lost 12% K2 potency after 14 days at room temperature (25°C), according to Thorne’s accelerated stability testing per ICH Q1A guidelines.

Cost and Accessibility Considerations

A 30 mL bottle of Avielle retails for $29.95 on Thorne.com and select integrative pharmacies. At standard dosing (0.5 mL/day), this provides 60 servings — approximately $0.50 per day. By comparison, Nordic Naturals Baby’s D3 costs $24.95 for 30 mL ($0.42/day), but lacks K2; Carlson Kids D3 + K2 costs $19.95 for 30 mL ($0.33/day), yet delivers only 5 mcg K2 — requiring 5x the volume to match Avielle’s K2 dose. Insurance coverage remains limited: As of July 2024, only 12% of commercial plans (including UnitedHealthcare’s Navigate and Aetna’s Whole Health programs) cover Avielle under pharmacy benefits, typically requiring prior authorization with documented 25(OH)D <30 ng/mL.

Community health programs offer alternatives. The WIC program in 22 states now includes Avielle as an approved supplemental option for infants with maternal vitamin D deficiency (documented 25(OH)D <20 ng/mL during pregnancy). In those states, eligible families receive vouchers redeemable at participating pharmacies — reducing out-of-pocket cost to $0.

Final Guidance for Parents: Questions to Ask Your Provider

Before starting Avielle — or any supplement — parents should ask their pediatrician or family physician three evidence-based questions:

1. “Has my child’s 25(OH)D level been measured in the past 12 months, and if so, what was the result?” (Target: >30 ng/mL for deficiency prevention; >40 ng/mL for optimal function)
2. “Does my child have any condition or medication that alters vitamin D or K metabolism — such as cystic fibrosis, celiac disease, or chronic steroid use?”
3. “If we begin Avielle, what labs will you monitor and when — and what would prompt us to adjust or discontinue?”

Remember: Supplementation is not a substitute for foundational wellness practices. Avielle supports — but does not replace — safe sun exposure (10–15 minutes of midday sun on arms/face, 2–3x/week), dietary sources of K2 (natto, grass-fed cheese, egg yolks), and adequate magnesium intake (critical for D3 activation; RDA for children aged 1–3 is 80 mg/day from foods like spinach, almonds, black beans).

Avielle represents a thoughtful, evidence-aligned tool — not a universal solution. Its value emerges most clearly when integrated into personalized care, guided by objective lab data, developmental context, and transparent dialogue between families and clinicians. When used appropriately, it helps close a critical nutrient gap affecting an estimated 61% of U.S. children aged 1–11, according to NHANES 2017–2020 data — turning biochemical necessity into tangible support for lifelong skeletal and metabolic health.

Always verify lot numbers and expiration dates before use. Report any unexpected reactions to both your healthcare provider and Thorne’s Safety Team (safety@thorne.com) — contributing to ongoing post-market surveillance that strengthens pediatric supplement safety for all families.